Yangchun Du

2.0k total citations
55 papers, 1.2k citations indexed

About

Yangchun Du is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Yangchun Du has authored 55 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Psychiatry and Mental health, 14 papers in Pediatrics, Perinatology and Child Health and 12 papers in Oncology. Recurrent topics in Yangchun Du's work include Schizophrenia research and treatment (25 papers), Pharmaceutical studies and practices (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Yangchun Du is often cited by papers focused on Schizophrenia research and treatment (25 papers), Pharmaceutical studies and practices (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Yangchun Du collaborates with scholars based in United States, Canada and China. Yangchun Du's co-authors include Elliot Ehrich, Hiroko H. Dodge, Mary Ganguli, Graham Ratcliff, Chung-Chou H. Chang, Bernard L. Silverman, Richard Leigh-Pemberton, Maurizio Fava, Robert Risinger and Ryan Z. Turncliff and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and American Journal of Psychiatry.

In The Last Decade

Yangchun Du

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yangchun Du United States 16 617 256 145 127 117 55 1.2k
Spyridon Siafis Germany 22 985 1.6× 250 1.0× 119 0.8× 149 1.2× 258 2.2× 79 1.6k
Riccardo Torta Italy 24 559 0.9× 270 1.1× 115 0.8× 87 0.7× 207 1.8× 74 1.7k
Judith C. Kando United States 15 741 1.2× 264 1.0× 99 0.7× 68 0.5× 135 1.2× 40 1.2k
René Swanink United States 12 839 1.4× 552 2.2× 84 0.6× 81 0.6× 98 0.8× 20 1.3k
Wolfgang Fleischhacker Austria 14 922 1.5× 154 0.6× 182 1.3× 137 1.1× 238 2.0× 28 1.5k
Stephanie Feldman United States 24 585 0.9× 209 0.8× 150 1.0× 209 1.6× 178 1.5× 48 1.2k
Thomas J. Arndt United States 8 760 1.2× 171 0.7× 105 0.7× 131 1.0× 147 1.3× 8 1.1k
Subramoniam Madhusoodanan United States 21 779 1.3× 220 0.9× 95 0.7× 60 0.5× 175 1.5× 62 1.5k
John Panagides United States 22 1.0k 1.7× 446 1.7× 154 1.1× 109 0.9× 89 0.8× 71 1.5k

Countries citing papers authored by Yangchun Du

Since Specialization
Citations

This map shows the geographic impact of Yangchun Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yangchun Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yangchun Du more than expected).

Fields of papers citing papers by Yangchun Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yangchun Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yangchun Du. The network helps show where Yangchun Du may publish in the future.

Co-authorship network of co-authors of Yangchun Du

This figure shows the co-authorship network connecting the top 25 collaborators of Yangchun Du. A scholar is included among the top collaborators of Yangchun Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yangchun Du. Yangchun Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Du, Yangchun, et al.. (2024). Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours. BioMedical Engineering OnLine. 23(1). 41–41. 14 indexed citations
2.
Piha‐Paul, Sarina A., Justin Call, Alexander I. Spira, et al.. (2024). Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).. Journal of Clinical Oncology. 42(16_suppl). 2587–2587. 1 indexed citations
3.
Liu, Jindou, Hao Deng, Yangchun Du, et al.. (2023). Identifying 2PHDO as a SOCE Inhibitor from Chinese Herbal Extracts. Current Pharmaceutical Biotechnology. 27.
4.
5.
Kelly, Deanna L., et al.. (2021). Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry Research. 302. 114030–114030. 6 indexed citations
6.
7.
8.
Lauriello, John, Amy Claxton, Yangchun Du, & Peter J. Weiden. (2020). Beyond 52-Week Long-Term Safety. The Journal of Clinical Psychiatry. 81(5). 4 indexed citations
9.
Miller, Brian J., Amy Claxton, Yangchun Du, Peter J. Weiden, & Steven G. Potkin. (2019). Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia Research. 208. 44–48. 6 indexed citations
10.
Citrome, Leslie, Yangchun Du, & Peter J. Weiden. (2019). <p>Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm</p>. Neuropsychiatric Disease and Treatment. Volume 15. 2639–2646. 6 indexed citations
11.
Sun, Lei, et al.. (2019). <p>Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet</p>. Drug Design Development and Therapy. Volume 13. 2941–2955. 18 indexed citations
12.
Weiden, Peter J., Yangchun Du, Chih‐Chin Liu, & Arielle D. Stanford. (2018). Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS Spectrums. 24(4). 419–425. 5 indexed citations
13.
Citrome, Leslie, Robert Risinger, Andrew J. Cutler, et al.. (2017). Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study. CNS Spectrums. 23(4). 284–290. 11 indexed citations
14.
McEvoy, Joseph P., et al.. (2017). Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. The Journal of Clinical Psychiatry. 78(8). 1103–1109. 12 indexed citations
15.
Potkin, Steven G., Robert Risinger, Yangchun Du, et al.. (2017). Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophrenia Research. 190. 115–120. 12 indexed citations
16.
Nasrallah, Henry A., John W. Newcomer, Robert Risinger, et al.. (2016). Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. The Journal of Clinical Psychiatry. 77(11). 1519–1525. 29 indexed citations
17.
Meltzer, Herbert Y., Robert Risinger, Henry A. Nasrallah, et al.. (2015). A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 76(8). 1085–1090. 100 indexed citations
18.
Citrome, Leslie, Yangchun Du, Robert Risinger, et al.. (2015). Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology. 31(2). 69–75. 17 indexed citations
19.
Himali, Jayandra J., Alexa Beiser, Sherral Devine, et al.. (2013). The Framingham Heart Study Clock Drawing Performance: Normative Data from the Offspring Cohort. Experimental Aging Research. 39(1). 80–108. 21 indexed citations
20.
Ganguli, Mary, Yangchun Du, Hiroko H. Dodge, Graham Ratcliff, & Chung-Chou H. Chang. (2006). Depressive Symptoms and Cognitive Decline in Late Life. Archives of General Psychiatry. 63(2). 153–153. 263 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Spyridon Siafis Breakdown of academic impact, for papers by Riccardo Torta Breakdown of academic impact, for papers by Judith C. Kando Breakdown of academic impact, for papers by René Swanink Breakdown of academic impact, for papers by Wolfgang Fleischhacker Breakdown of academic impact, for papers by Stephanie Feldman Breakdown of academic impact, for papers by Thomas J. Arndt Breakdown of academic impact, for papers by Subramoniam Madhusoodanan Breakdown of academic impact, for papers by John Panagides
Rankless by CCL
2026